Stablepharma Limited

Stablepharma develops fridge-free, extended shelf-life versions of vaccines and pharmaceuticals to reduce waste and CO2.

Founded 2012

Bath, United Kingdom 22 employees Total: $10.50M Biotechnology, Health Care +3

Stablepharma Limited is an innovative biopharmaceutical company that aims to revolutionize vaccine storage with its novel technology, StablevaX™. The company's primary goal is to provide fridge-free vaccines, reduce vaccine wastage, and ultimately save lives. Founded in 2012, Stablepharma is dedicated to improving health outcomes for individuals at risk of vaccine-preventable diseases, particularly children and adults. The company's flagship product, SPVX02, is the world's first fridge-free vaccine for Tetanus and Diphtheria. StablevaX is a game-changing technology that offers an extended shelf-life, reduces CO2 footprint, and eliminates the need for refrigeration during vaccine storage and distribution. According to the WHO, approximately 50% of all vaccines manufactured are wasted due to cold chain failures, making Stablepharma's mission critical in addressing this issue. The company's recent £231.97K Equity Crowdfunding investment from Crowdcube on 29 September 2023 underscores investor confidence in Stablepharma's innovative approach to vaccine development and storage. Stablepharma's focus on Biotechnology, Health Care, and Pharmaceutical industries positions it at the forefront of pioneering solutions in global healthcare. With its headquarters in the United Kingdom, the company is well positioned to drive impactful change in the vaccine landscape, benefiting individuals worldwide.

Funding Stage	Amount	Investors	Lead Investors	Date
Funding Round	£1.83M	-		30 Apr 2024
Funding Round	£1.60M	-		29 Sep 2023
Grant	Undisclosed	1	Innovate UK	06 Sep 2023
Series A	£3.21M	-		14 Jul 2022
Series A	£2.00M	1	Ascension Ventures	07 Aug 2021
Equity Crowdfunding	£1.36M	-		30 Jun 2019
Seed Round	£220.00K	-		01 Jul 2017
Angel Round	£105.00K	-		31 Dec 2016
Seed Round	€50.00K	1	EASME - EU Executive Agency for SMEs	09 Jan 2015
Seed Round	£125.00K	1	SFC Capital	01 Jun 2013

Funding Stage

Amount

Investors

Lead Investors

Date

Funding Round

£1.83M

30 Apr 2024

Funding Round

£1.60M

29 Sep 2023

Grant

Undisclosed

Innovate UK

06 Sep 2023

Series A

£3.21M

14 Jul 2022

Series A

£2.00M

Ascension Ventures

07 Aug 2021

Equity Crowdfunding

£1.36M

30 Jun 2019

Seed Round

£220.00K

01 Jul 2017

Angel Round

£105.00K

31 Dec 2016

Seed Round

€50.00K

EASME - EU Executive Agency for SMEs

09 Jan 2015

Seed Round

£125.00K

SFC Capital

01 Jun 2013

FAQ About Stablepharma Limited

Stablepharma develops fridge-free, extended shelf-life versions of vaccines and pharmaceuticals to reduce waste and CO2.

Stablepharma Limited was founded in 2012.

Stablepharma Limited is headquartered in Bath, United Kingdom.

Stablepharma Limited operates in Biotechnology, Health Care, Health and Wellness, Medical Devices and Pharmaceutical. Its work centres on biopharmaceutical, vaccine technology, fridge-free vaccines and vaccine wastage reduction.

Stablepharma Limited has approximately 22 employees.

Stablepharma Limited has completed 10 funding rounds, raising a total of $10.50M.

Top alternatives and competitors to Stablepharma Limited include KAICO Ltd., HilleVax, TheraJect, Inc., Vaccine Systems, LLC, Vaxxas. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Stablepharma Limited and KAICO Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Stablepharma Limited

Funding Rounds & Investors (10)

Stablepharma Limited Alternatives & Competitors

FAQ About Stablepharma Limited